Literature DB >> 16597597

The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.

Tiemo Katzenberger, Celine Petzoldt, Sylvia Höller, Uwe Mäder, Jörg Kalla, Patrick Adam, M Michaela Ott, Hans Konrad Müller-Hermelink, Andreas Rosenwald, German Ott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16597597     DOI： 10.1182/blood-2005-10-4079

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  36 in total

Review 1.  Role of allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  Jonathon B Cohen; Linda J Burns; Veronika Bachanova
Journal:  Eur J Haematol       Date:  2014-10-18       Impact factor: 2.997

2.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 3.  Mantle cell lymphoma: evolving novel options.

Authors:  Andre Goy
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

4.  Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.

Authors:  Matthew A De Niear; John P Greer; Adam Seegmiller; Louise A Mawn
Journal:  Ocul Oncol Pathol       Date:  2018-11-16

Review 5.  Mantle cell lymphoma: observation to transplantation.

Authors:  Babak Rajabi; John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2015-02

6.  Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.

Authors:  Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

7.  A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.

Authors:  André Goy; Francisco J Hernandez-Ilzaliturri; Brad Kahl; Peggy Ford; Ewelina Protomastro; Mark Berger
Journal:  Leuk Lymphoma       Date:  2014-05-06

Review 8.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

9.  Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network.

Authors:  Wolfram Klapper; Eva Hoster; Olaf Determann; Ilske Oschlies; Jeroen van der Laak; Françoise Berger; Heinz Wolfram Bernd; José Cabeçadas; Elias Campo; Sergio Cogliatti; Martin Leo Hansmann; Philip M Kluin; Roman Kodet; Yuri A Krivolapov; Christoph Loddenkemper; Harald Stein; Peter Möller; Thomas E F Barth; Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Stefano Pileri; Elisabeth Ralfkiaer; Grzegorz Rymkiewicz; Johan H van Krieken; Hans Heinrich Wacker; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Journal:  J Hematop       Date:  2009-06-16       Impact factor: 0.196

10.  Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Authors:  R Schaffel; C V Hedvat; J Teruya-Feldstein; D Persky; J Maragulia; D Lin; C S Portlock; C H Moskowitz; A D Zelenetz
Journal:  Ann Oncol       Date:  2010-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.